{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:33:14Z","timestamp":1761060794422,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofvascularsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.avsg.2019.02.033","type":"journal-article","created":{"date-parts":[[2019,5,8]],"date-time":"2019-05-08T10:23:48Z","timestamp":1557311028000},"page":"286-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Anticoagulant Effect of Standard Dose Heparin During Peripheral Endovascular Intervention"],"prefix":"10.1016","volume":"60","author":[{"given":"Emelie","family":"Nissborg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl-Magnus","family":"Wahlgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.avsg.2019.02.033_bib1","first-page":"CD002071","article-title":"Antiplatelet and anticoagulant drugs for prevention of restenosis\/reocclusion following peripheral endovascular treatment","author":"Robertson","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.avsg.2019.02.033_bib2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature06797","article-title":"Triggers, targets and treatment for thrombosis","volume":"451","author":"Mackman","year":"2008","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.avsg.2019.02.033_bib3","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.ejvs.2006.09.024","article-title":"Inter-society consensus for the management of peripheral arterial disease (TASC II)","volume":"33","author":"Norgren","year":"2007","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"1 Suppl","key":"10.1016\/j.avsg.2019.02.033_bib4","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.avsg.2019.02.033_bib5","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00270-013-0741-9","article-title":"Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease","volume":"37","author":"Rossi","year":"2014","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.avsg.2019.02.033_bib6","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/01.CIR.103.7.961","article-title":"Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials","volume":"103","author":"Chew","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2019.02.033_bib7","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1161\/CIRCINTERVENTIONS.110.957381","article-title":"Defining the optimal degree of heparin anticoagulation for peripheral vascular interventions: insight from a large regional, multicenter registry","volume":"3","author":"Kasapis","year":"2010","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2019.02.033_bib8","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00270-013-0558-6","article-title":"Periprocedural prophylactic antithrombotic strategies in interventional radiology: current practice in The Netherlands and comparison with the United Kingdom","volume":"36","author":"Wiersema","year":"2013","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.avsg.2019.02.033_bib9","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/bja\/ael194","article-title":"Anticoagulation monitoring during vascular surgery: accuracy of the Hemchron low range activated clotting time (ACT-LR)","volume":"97","author":"Tremey","year":"2006","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.avsg.2019.02.033_bib10","first-page":"1456298","article-title":"The use of heparin during endovascular peripheral arterial interventions: a synopsis","volume":"2016","author":"Wiersema","year":"2016","journal-title":"Scientifica (Cairo)"},{"key":"10.1016\/j.avsg.2019.02.033_bib11","doi-asserted-by":"crossref","first-page":"CR105","DOI":"10.12659\/MSM.882465","article-title":"The influence of heparin resistance on postoperative complications in patients undergoing coronary surgery","volume":"18","author":"Knapik","year":"2012","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.avsg.2019.02.033_bib12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1213\/ANE.0b013e31827e4e62","article-title":"Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass","volume":"116","author":"Finley","year":"2013","journal-title":"Anesth Analg"},{"key":"10.1016\/j.avsg.2019.02.033_bib13","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ejvs.2017.07.006","article-title":"Individual differences in heparin sensitivity and their effect on heparin anticoagulation during arterial vascular surgery","volume":"54","author":"Veerhoek","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.avsg.2019.02.033_bib14","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1093\/eurheartj\/ehw061","article-title":"Anticoagulation in coronary intervention","volume":"37","author":"Zeymer","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.avsg.2019.02.033_bib15","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1161\/01.CIR.0000139868.53594.24","article-title":"Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials\u00a0of percutaneous coronary intervention","volume":"110","author":"Brener","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2019.02.033_bib16","first-page":"351","article-title":"Defining optimal activated clotting time for percutaneous coronary intervention: a systematic review and Bayesian meta-regression","volume":"89","author":"Motillo","year":"2017","journal-title":"Catheter Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2019.02.033_bib17","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","article-title":"2014 ESC\/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic surgery (EACTS) developed with the interventions (EAPCI)","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"issue":"3 Suppl","key":"10.1016\/j.avsg.2019.02.033_bib18","doi-asserted-by":"crossref","first-page":"576S","DOI":"10.1378\/chest.126.3_suppl.576S","article-title":"Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCp Conference on Antithormbotic and Thrombolytic therapy","volume":"126","author":"Popma","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.avsg.2019.02.033_bib19","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2019.02.033_bib20","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/oxfordjournals.eurheartj.a015308","article-title":"A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty","volume":"18","author":"Boccara","year":"1997","journal-title":"Eur Heart J"},{"key":"10.1016\/j.avsg.2019.02.033_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1051\/ject\/201850005","article-title":"STS\/SCA\/AmSECT clinical practice guidelines: anticoagulation during cardiopulmonary bypass","volume":"50","author":"Shore-Lesserson","year":"2018","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.avsg.2019.02.033_bib22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.jvca.2017.05.043","article-title":"Con: activated clotting time should not be monitored during heparinization for vascular surgery","volume":"32","author":"Wolo","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"10.1016\/j.avsg.2019.02.033_bib23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-8703(98)70223-6","article-title":"How does warfarin affect the activated coagulation time?","volume":"136","author":"Chang","year":"1998","journal-title":"Am Heart J"},{"key":"10.1016\/j.avsg.2019.02.033_bib24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/CIRCEP.113.979088","article-title":"Impact of international normalized ratio and activated clotting time on unfractionated heparin dosing during ablation of atrial fibrillation","volume":"6","author":"Hamam","year":"2013","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.avsg.2019.02.033_bib25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/bmj.316.7136.969","article-title":"Benefit of heparin in peripheral venous and arterial catheters: systematic review and meta-analysis of randomised controlled trials","volume":"316","author":"Randolph","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2019.02.033_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1051\/ject\/201244015","article-title":"Comparison of point-of-care activated clotting time systems utilized in a single pediatric institution","volume":"44","author":"Ojito","year":"2012","journal-title":"J Extra Corpor Technol"},{"key":"10.1016\/j.avsg.2019.02.033_bib27","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1160\/TH08-08-0528","article-title":"Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation","volume":"101","author":"Chia","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.avsg.2019.02.033_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1051\/ject\/201850038","article-title":"Clinical evaluation of measuring the ACT during elective cardiac surgery with two different devices","volume":"50","author":"Falter","year":"2018","journal-title":"J Extra Corpor Technol"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509619302882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509619302882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:53:49Z","timestamp":1760187229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509619302882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":28,"alternative-id":["S0890509619302882"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2019.02.033","relation":{},"ISSN":["0890-5096"],"issn-type":[{"type":"print","value":"0890-5096"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anticoagulant Effect of Standard Dose Heparin During Peripheral Endovascular Intervention","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2019.02.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}